Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QMF149 vs mometasone furoate in asthma
NCT02892344Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in asthma (2 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
indacaterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02892344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892344.